Abstract We conducted a randomized clinical trial in 45 patients with resected AJCC stage IIB-IV melanoma to characterize cellular and molecular events at sites of immunization with incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA. At a primary vaccine site, all patients received a multi-peptide melanoma vaccine in IFA. At a replicate vaccine site, which was biopsied, group 1 received IFA only; group 2 received vaccine in IFA. Lymphocytes isolated from replicate vaccine site microenvironments (VSME) were compared to time-matched peripheral blood mononuclear cells (PBMC) in ELISpot and flow cytometry assays. Compared to PBMC, the VSME had fewer naïve and greater proportions of effector memory CD8
Introduction
Clinical activity of cancer vaccines is now supported by approval of sipuleucel-T (Provenge) for prostate cancer, and improved clinical outcome of advanced melanoma by adding a melanoma peptide vaccine to high-dose IL-2 [1] . However, melanoma vaccines alone have induced objective clinical regressions in only 3-6 % of patients [2] , despite inducing circulating anti-tumor T cells in 70-100 % of patients [3, 4] . Unfortunately, the immune responses are often of low magnitude and duration [3] , which likely limits their clinical activity and may explain in part the low clinical response rates.
A vaccine adjuvant is necessary to activate dendritic cells (DCs) and to induce a favorable immunologic milieu; however, little is known about the cellular and molecular events induced by such adjuvants. A widely used adjuvant is incomplete Freund's adjuvant (IFA), which was developed in the 1930s to induce antibody responses to viral proteins [5] . It is not clear what adjuvants are best to induce durable T cell responses to defined cancer antigens. We have previously reported a histologic analysis of sites of immunization with peptides in an emulsion with Montanide ISA-51 (an IFA), using immunohistochemistry, which suggested that the vaccine site microenvironment (VSME) is not optimized for induction of strong Th1/Tc1 responses, with induction, instead, of FoxP3
? cells and of eosinophils, suggestive of a Th2 dominant microenvironment [6] .
Immunization in IFA creates a depot of antigen plus adjuvant and can lead to chronic inflammation in the VSME that is clinically prominent, and may persist for years. Chronic inflammation can induce lymphoid neogenesis and development of tertiary lymphoid organs (TLO) [7] [8] [9] . This can occur at sites of cancer vaccines, where lymphoid aggregates contain separate B and T cell areas, mature dendritic cells, high endothelial venule (HEV)-like vessels and lymphoid cytokines [10] . Thus, vaccines containing IFA may induce a VSME that supports antigen presentation in the vaccine site itself [10] ; however, lymphoid aggregates in the VSME may lack full function of a lymph node. Other data raise questions about whether the chronic depot of IFA-containing vaccines may have negative effects on persistent systemic immunity and tumor control: in murine models, activated, antigen specific T cells traffic selectively to such vaccine sites rather than to tumor, and may die there [11] . These findings remain to be confirmed in humans. To address whether the VSME induced by peptide vaccines in IFA may recruit and/or retain antigen-specific T cells in humans, we have evaluated the phenotype and function of antigen-specific CD8 ? T cells from vaccine sites and PBMC. We present data that the VSME contains antigen-reactive effector memory T cells that are either exhausted or in a prolonged refractory state, and that are retained in the VSME, with high expression of retention integrins (a1b1 and aEb7).
Materials and methods

Patient selection
Specimens for this study were obtained in a clinical trial of a multi-peptide vaccine for melanoma: NCT00705640, University of Virginia (Mel48). Patients with resected AJCC stage IIB-IV arising from cutaneous, mucosal, ocular, or unknown primary site were eligible. Inclusion criteria included: expression of HLA-A1, A2, A3, or A11; age of 18 years or greater; ECOG performance status 0-1; adequate blood counts, liver, and renal function; negative serologies for HIV and Hepatitis C; and ability to give informed consent. Exclusion criteria included: multiple brain metastases; cytotoxic chemotherapy, interferon therapy, or radiation within the preceding 4 weeks; known or suspected allergies to any vaccine component; pregnancy; body weight less than 110 lbs; use of steroids; or Class III, IV heart disease. Patients were studied following informed consent, with Institutional Review Board (IRB/HSR #13498) and FDA approval (BB-IND #12191).
Patient assignment and study protocol
Patients were randomized to one of two groups, and one of five arms within each group (Fig. 1) . All received the full vaccine (12 Class I MHC restricted melanoma peptides and a tetanus helper peptide emulsified in IFA) at the primary vaccine site (days 1, 8, 15, 29, 36 , and 43), plus a 2nd vaccine at a replicate vaccine site, where the injectate differed between the two study groups: IFA only (group 1) or full vaccine (group 2). Within each study group, there were five arms: with excisional biopsy of the replicate site: pre-vaccination (week 0, Arm A), 1 week after the first vaccine (week 1, Arm B), 1 week after the third vaccination (week 3, arm C), 1 week after the sixth vaccination (week 7, arm D), or 6 weeks after the sixth vaccination (week 12, arm E).
Vaccine preparation and dosage
The full vaccine consisted of 12 class I MHC-restricted melanoma peptides (12-MP vaccine-Supplemental Table  S1 ; 50 lg each peptide) and a tetanus helper peptide (Peptide-tet; 100 lg) in 0.5 mL aqueous solution, emulsified 1:1 with 0.5 mL Montanide ISA-51. The total injected volume was 1.0 mL, one half given subcutaneously (s.c.), the other half intradermally (i.d.), through a single skin puncture. The replicate vaccine containing only adjuvant was an emulsion of saline (0.5 mL) plus 0.5 mL Montanide ISA-51, also administered s.c. and i.d.
Design and sample size
This was a pilot study to obtain preliminary measures of several pre-specified endpoints of interest. For sample size determination, we characterized power in terms of effect, with planned use of regression models maximizing power for small sample size. Four patients were to be accrued to each biopsy time point for each treatment group. Maximum accrual to the study was estimated to be 44 subjects in order to accrue the target 36 eligible subjects required to meet the study objectives, plus a 5 % ineligibility rate and over-accrual of subjects scheduled to have biopsies at the later time points. Total accrual was 45.
ELISpot
ELISpot assays for interferon gamma (IFN-c) were performed on PBMCs and on lymphocytes from the VSME (Fig. 1 ). Assays were performed directly ex vivo after cryopreservation (direct ELISpot), as previously reported [12] . Criteria for positive immunologic response were: magnitude of response Ctwo-fold pre-vaccination value and experimental negative control, an increase of at least 0.02 % of CD8
? T cells over negative control, and no overlap between the 1SD intervals of the response and negative controls [12] . Calculated interassay coefficients of variation for normal donor PBMC for high and low responders to CEF peptides were 18 and 23 %, respectively.
Immunostaining and multi-parametric flow cytometry Single-cell suspensions of cryopreserved PBMC and mononuclear cell specimens isolated from vaccine site biopsies using methods previously described [12] were thawed in warm RPMI-1640 (Life Technologies: Grand Island, NY) medium containing 5 % fetal bovine serum (FBS; Sigma-Aldrich: St. Louis, MO), and 100,000 U/ml deoxyribonuclease I (Cat. # LS00219; Worthington Biochemical Co.: Lakewood, NJ). Cells were washed in phosphate buffered saline (PBS) and were labeled with the LIVE/DEAD Ò Fixable Aqua dead cell stain (Life Technologies) for viability according to manufacturer's instructions. Aliquots of Aqua-labeled cells were added to wells containing mixtures of Class I MHC-peptide multimers (Beckman Coulter; Indianapolis, IN) relevant to the patient's HLA type for a total volume of 25 lL, as described [13] . Also, a pentamer (Proimmune; Oxford, UK) for SLFRAVITK (MAGE-A1 96-104 ) was incorporated in the HLA-A3 pool of tetramers. After incubation at 4°C for 20 min, 25 lL labeled antibody mixtures for integrins, homing receptors, chemokine receptors, and activation/ maturation markers were added to the cell suspensions (details in Supplemental Table S2 ). then incubated an additional 20 min at 4°C, washed twice in FACS buffer (PBS ? 2 % FBS), then fixed in 2 % paraformaldehyde (Sigma-Aldrich) in PBS for 10 min at room temperature, and washed once. Immunostained cells were held overnight at 4°C then acquired on a CyAn ADP LX 9 color flow cytometer (Beckman Coulter) equipped with 3 lasers. Flow cytometry data were analyzed with FlowJo version 8.8.6 (Tree Star; Ashland, OR), gated on viable, single cell populations.
In vitro stimulation of vaccine site cell suspensions Cells were thawed, counted, and incubated with a pool of the 12 melanoma peptides (40 lg/ml each) for 2 h, washed and cultured with IL-2 (20 IU/mL) in culture medium (RPMI1640 ? 10 % human AB serum). Cultures were fed with culture media with IL-2 as needed. No media replacement was necessary. On day 14, cells were collected and viable cell recovery determined.
Intracellular cytokine stimulation and staining
Cells were stimulated with peptide-pulsed C1R-A2 cells (T:APC ratio 2:1) or with PMA ? ionomycin (50 ng/mL and 1 lM, respectively). Cells were incubated 4 h in AIM V ? 5 % HuAB serum in the presence of GolgiPlug (BDBiosciences; San Jose, CA), then washed in PBS and labeled with Aqua 30 min at 4°C. Pooled tetramers, or the irrelevant tetramer were added and incubated 45 min at 4°C. Cells were washed and fixative (BioLegend; San Diego, CA) added for 20 min at room temperature. Cells were washed twice and left overnight at 4°C, then permeabilized, to which was added a mixture of antibodies in permeabilization buffer (BDBiosciences) consisting of anti-CD8-FITC (Beckman Coulter), CD3 Pacific Blue, CD4-PE-Texas red, CD19 PE-Texas red (Invitrogen; Grand Island, NY), and interferon-gamma-APC (eBioscience; San Diego, CA). Cells were incubated 60 min at 4°C, then washed 3 times in permeabilization buffer and twice in PBS ? 0.1 % BSA ? 0.1 % sodium azide. Cells were acquired on a Beckman Coulter CyAn ADP LX 9 Color flow cytometer and analyzed using FlowJo software.
Statistical analysis
For each assay, data from all patients with available samples from the vaccine site and time-matched PBMC were evaluated using SPSS 20 (IBM: Armonk, NY). Linear regression models were used to assess the difference between vaccine site values and time-matched PBMC, accounting for two variables: Patient group and Study Arm (biopsy time point). To minimize the impact of outliers in this small patient population and to satisfy model assumptions, square root transformation of endpoints was employed for all analyses. In analyses of tetramer pos and tetramer neg subsets of cells, samples containing fewer than 5 tetramer pos cells were excluded, which resulted in the elimination of 1 group 2C patient from CCR7/CD45RA, CXCR3, CLA and CD62L analyses. In this pilot study, no adjustments were made for multiple comparisons. All tests were two-sided and considered significant for p B 0.05. All results are reported after adjusting for patient group and study arm (time of biopsy).
Results
Patients studied
Forty-five patients with resected AJCC stage IIB-IV melanoma were enrolled in a clinical trial of a multi-peptide vaccine (Mel 48, Fig. 1 ), from which histologic findings have been reported [6] . All were vaccinated with 12MP plus tetanus helper peptide in a primary vaccine site. Each had ''replicate vaccine'' injection at a second site, which was biopsied. The replicate vaccine consisted of either IFA alone (group 1), or IFA with peptides (group 2). Patients enrolled in the two study arms were similar (Table 1) . Replicate site biopsies were obtained in 38 patients (84 %). Vaccine site biopsies from study arms A (week 0), B (week 1), and E (week 12) contained insufficient lymphocytic infiltrates for both ELIspot and flow cytometric evaluation. Data from both VSME and time matched PBMC were obtained from 13 patients from vaccine site biopsies at weeks 3 and 7: 2, 3, 5, and 3 in groups 1C, 1D, 2C, and 2D, respectively.
Composition of cells in the VSME
CD8
? T cells were characterized based on CCR7 and CD45RA expression [14] . Compared to PBMC, the VSME had fewer naïve cells (T naïve , CD45RA
? /CCR7 ? ) and greater proportions of effector memory cells (T EM ,  CD45RA neg /CCR7 neg , Fig. 2 ). Among tetramer neg cells, T naïve were lower in VSME than PBMC (p = 0.003) and T EM were higher (p \ 0.001, Fig. 2a, c) . Among tetramer pos cells, T EM were more prevalent in the VSME than in PBMC (p = 0.033, Fig. 2d ). Proportions of central memory T cells (T CM , CD45RA neg /CCR7 ? ) were very low for all samples, were slightly higher in the VSME than PBMC overall (p = 0.004), but not among tetramer pos cells (Supplemental Fig. SF1 ). There were no significant differences in CD45RA pos effector memory (T EMRA, CD45RA pos /CCR7 neg ) proportions between sites (Supplemental Fig. SF1 ).
Activation and antigen specificity in the vaccine site Among all subjects, CD69
? CD8 ? T cells were enriched in the VSME compared to PBMC (p \ 0.001, Fig. 3b ). The proportion of tetramer pos cells in VSME trended higher than in PBMC overall but did not reach statistical significance (Fig. 3d) ; review of graphical data prompted examination of group 2 alone: among those patients with antigen in the biopsied VSME, there were more tetramer pos CD8
?
T cells than in PBMC (p = 0.003 Fig. 3d) . CD4 Supplemental Table S4 .
Dysfunction of antigen-specific cells
Antigen-specific CD8
? T cells in the VSME appeared to be dysfunctional for all patients, regardless of the presence or absence of peptides at the VSME. Despite increased ? T cells compared to peripheral blood. Phenotypes of CD8
? T cells (T CD8 ) were determined by multi-parameter flow cytometry staining with CCR7 and CD45RA. Cells were sorted by their ability to bind to tetramers relevant to the HLA type of the patient. Gating was performed on live, singlet, CD8
? /CD4 ? T cells in the VSME than in PBMC (p = 0.033, Supplemental Fig. SF2 ). Vaccine sites contained fewer functional cells per tetramer pos T cells than PBMC (p = 0.053, Fig. 3e ).
To evaluate preliminarily whether the apparent dysfunction of tetramer pos cells in the VSME was reversible, a stimulated ELISpot assay was performed. Cryopreserved cell suspensions from 5 vaccine site biopsies were stimulated with the 12MP in vitro and placed in a 14 day culture with IL-2, using methods previously reported [4] . Lymphocytes expanded very poorly in all samples; only 2 yielded adequate cell numbers for flow cytometry (viable cells only 3 and 15 % of the input cell number), which revealed no expansion of tetramer pos cells after stimulation (data not shown).
Expression of homing molecules
The VSME overall contained greater proportions of T cells expressing the chemokine receptor CXCR3 than PBMC (Fig. 4a, b) . This was true among CD4
? T cells (p \ 0.001, Fig. 4c ), tetramer neg and tetramer pos CD8 ? T cells (p = 0.001, p \ 0.001, respectively, Fig. 4a, b) .
Cutaneous leukocyte antigen (CLA) was inconsistently elevated in the VSME. Among tetramer neg CD8 ? T cells, 
CLA
? cells were increased in the VSME (p = 0.004, Supplemental Fig. SF3a ), but no evident enhancement of CLA was observed among tetramer pos CD8 ? T cells in the VSME (Supplemental Fig. SF3b) .
CD62L (L-selectin), a HEV homing molecule, was present on PBMC, but CD62L
? CD8 ? T cells were notably decreased or absent in all VSME, for both tetramer neg and tetramer pos subsets of VSME CD8 ? T cells (p = 0.004; p \ 0.001, respectively; Supplemental Fig. SF3c, d ).
Increased expression of retention integrins
Expression of retention integrins aEb7 and a1b1 was elevated in the VSME, particularly in group 2 (Fig. 5) . Among tetramer neg CD8 ? T cells aEb7 expression was higher in the VSME than in PBMC (p \ 0.001, Fig. 5a ). Among tetramer pos CD8 ? T cells in the vaccine site, aEb7 expression was not significantly increased in this small sample of patients; however, graphical depiction of the data showed that the greatest aEb7 expression was among tetramer positive cells in group 2 (Fig. 5b) : average percentages of cells expressing aEb7 in VSME and PBMC were 30 and 16 %, respectively, at week 3 and 50 and 10 %, respectively, at week 7 (Fig. 5b) . In all patients, aEb7 was nearly absent from tetramer neg cells in PBMC at every time point.
The proportion of CD8 ? T cells expressing a1b1 was higher in the VSME than PBMC, for both tetramer neg (p \ 0.001, Fig. 5c ) and tetramer pos CD8 ? T cells (p = 0.001, Fig. 5d ). Group 2 VSME had highly elevated a1b1 expression among tetramer pos cells, with means of 74 % expressing it at week 3 ( Fig. 5d) and 78 % at week 7. In matched PBMC, a1b1
? proportions of tetramer pos CD8 ? T cells averaged 24 % at week 3 and 30 % at week 7. In all patients, 5 % or less of tetramer neg cells in PBMC were a1b1
? at any time point.
Differences between study groups and time points
For most measures evaluated, there were no statistically significant differences between patients in Groups 1 and 2. However, expression of retention integrins was higher in group 2 VSME samples (IFA and peptides) than in group 1 (IFA alone), among tetramer neg CD8 ? T cells, for aEb7 (p = 0.008) and for a1b1 (p = 0.015). Elevated VSME expression of a1b1 among tetramer pos CD8 ? T cell trended toward a greater effect in group 2 (p = 0.120).
Similarly, the effect size of the difference between VSME and PBMC did not differ significantly from week 3 to 7 for most measures, except that greater numbers of ELISpot ? T cells were observed in the VSME week 7 than week 3 (p = 0.017). Comparing ELISpot ? to tetramer pos ratios, a smaller proportion of functional cells was observed in the vaccine site at week 3 than at week 7 (p = 0.059).
Discussion
We have previously reported features of lymphoid neogenesis in the VSME after IFA-based vaccines [10] . However, it is not clear if the resulting lymphoid aggregates are fully functional TLO. The findings of the present study suggest that they are not fully functional. TLO are characterized by high endothelial venules expressing peripheral node addressin [PNAd, which binds CD62L (L-selectin) on lymphocytes] and also by high levels of CCL19 and CCL21, ligands for CCR7. In the VSME lymphoid aggregates, we might anticipate an enrichment of T cell populations expressing CCR7 and CD62L, including naïve T cells and T CM . Instead, we find that in all patients, including those receiving only IFA at the vaccine site biopsied, the VSME CD8
? T cells are dominated by a large population of T EM phenotype with moderate proportions of T EMRA and scant T naive and T cm (Fig. 2, Supplemental Fig.  SF1) . Similarly, cells bearing CD62L are significantly reduced or absent in the VSME (Supplemental Fig. SF3 ).
Low numbers of T naïve in the vaccine site may reflect a return of T naïve to circulation after encountering the VSME or in situ conversion to a memory phenotype in the VSME after exposure to antigen. Despite loss of CCR7, T EM cells typically display other chemokine receptors and adhesion molecules required for homing to inflamed tissues; thus, T EM in the vaccine site may also be recruited from circulation and retained. The dominance of memory cells in the VSME of group 2 is counterintuitive, as peptide antigens administered in IFA emulsion might be expected to activate memory cells and to convert them to effectors. However, most T cells in the VSME are not immediately adjacent to vaccine emulsion depot, which resides in the tissue as small, loculated islands evident in histologic sections [10] . Also, the half-lives of peptides in our vaccine are short [15] ; they may be degraded before encountering dermal perivascular lymphocytes. Whether from conversion or lack of retention, the marked absence of T naïve in the VSME lymphoid aggregates suggests that these sites are not fully functional TLO, since higher proportions of naïve cells are found in normal nodes.
In a murine model of vaccination for melanoma, activated, antigen-specific T cells traffic to vaccine sites containing IFA plus peptide, and the vaccine site acts as a sink or graveyard for these tumor-specific T cells [11] . Several findings from the present study corroborate, in humans, what has been observed in the murine model: the VSME manifests a marked, long-lasting accumulation of activated (CD69 ? ) CD8 ? T cells, with concentration of antigenspecific (tetramer pos ) cells in the VSME in group 2 patients, in whom the vaccine site also contains peptide antigen. Our study differs from the murine model in that we observe T cell recruitment to the site injected with IFA alone. This may reflect that our examination takes place after repeated vaccination in the same site rather than observation after just one vaccine in the animal model. In previous immunohistochemical analysis of vaccine sites, we have demonstrated that single injections with adjuvant alone induce inflammatory dermal infiltrates which are transient and disorganized compared to those induced by repeated vaccination [10] . Though T cells in the VSME are clearly activated, evidence from the present study suggests that they are dysfunctional in their cytokine and proliferative responses to antigen, raising concerns about their ability to survive. In melanoma patients receiving vaccines in IFA, accumulation and persistent retention of T EM with subsequent depletion of these potential effectors at the vaccine site may limit vaccine-induced tumor control.
We have previously reported that both CD4 ? and CD8
? cells in the VSME induced with IFA are actively dividing, as manifest by Ki67 staining, and that T cells and mature DC are closely associated in the vaccine sites [10] , raising the possibility of in situ priming in the VSME, though such priming may be dysfunctional. To the extent that peptide may also bind to other cells (e.g. fibroblasts), in situ priming may be ineffective or even toleragenic [16] . On the other hand, when activated T cells reactive to peptides in the vaccine are evident in VSME without peptide, it is likely that they have been recruited to the site after activation. Ongoing recruitment of CD4 ? and CD8 ? T cells to all vaccine sites containing IFA may be mediated in part by chemokines attracting the high proportion of CXCR3 ? cells observed in the VSME compared to blood (Fig. 4) . However, CLA is not consistently increased despite the skin location of the vaccines.
Even in VSME containing peptide, well over 95 % of CD8
? T cells in the VSME are tetramer neg , indicating that the IFA-containing VSME appears to recruit and to stimulate T cells reactive to antigens other than those in the vaccine. The identity of those targets is not known, but we can hypothesize potential explanations: (1) recruitment of circulating T cells by cytokine-activated endothelium in the VSME, (2) decreased skin barrier function due to inflammation, with sensitization to environmental haptens and/or protein antigens in contact with the skin surface, and (3) reactivity to normal host skin antigens or melanocytic antigens due to injection of adjuvant into the skin.
T cell recruitment appears to lead to long-term retention, as substantial T cell aggregates in the VSME persist 6 weeks after the final vaccination [6] . Retention integrins provide a likely mechanism for the observed T cell sequestration within the VSME, as both aEb7 and a1b1 are significantly higher in sites where peptide antigen is present, with the most elevated expression in tetramer pos T cells in group 2 (Fig. 5) . aEb7 (CD103) binds E-cadherin on epithelial cells, and triggers CCR5 mediated recruitment and retention of T cells [17] . a1b1 (VLA-1) binds type IV collagen, and is critical for the development and maintenance of memory CD8
? T cells in peripheral tissues [18] . The significant elevation of aEb7 in group 2 vaccine sites over group 1 is likely related to the presence of antigen, with aEb7 upregulation dependent upon T cell receptor engagement with cognate antigen [19] . Systemic antitumor immunity may be compromised by recruitment and retention of T cells to the VSME, limiting circulation and homing to tumor.
Despite evident activation (CD69 positivity) of CD8 ? T cells in the VSME and increased antigen-specific cells in the group 2 VSME, lymphocytes retained in the VSME are strikingly dysfunctional (Fig. 3) . Consistent with previous murine model findings after similar vaccination with short peptides in IFA [11] , T cells in our human study appear refractory to correction with IL-2 and antigen stimulation, suggesting that activated CD8
? T cells within the VSME are in a refractory or exhausted state.
Vaccines containing IFA can be highly effective inducers of antibody responses; however, IFA may not be an optimal adjuvant for induction of T cell responses to peptides. Though sample size in these pilot data precludes definitive conclusions regarding the role of antigen in dysfunction of lymphoid aggregates, the study provides evidence that vaccine sites with IFA recruit and retain activated, dysfunctional CD8
? T cells, predominantly of effector memory phenotype. Selective retention of antigenspecific CD8
? T cells within the VSME is suggested by increased tetramer pos cells in the VSME of group 2 and high proportions of cells expression retention integrins. This may point to a significant mechanism underlying transient immune responses and low clinical response rates to peptide vaccines seen in the melanoma population to date. The same mechanism may interfere with combinations of T cell directed therapies (e.g. vaccines with adoptive T cell therapy, IL-2, or checkpoint blockade). This challenge may well be overcome by use of newer adjuvants and/or different vaccine formulations that avoid chronic inflammation in the VSME.
